Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies

Current Opinion in HIV and AIDS

Volumn 8, Issue 4, 2013, Pages 262-272

  Del Prete, Gregory Q ^a   Lifson, Jeffrey D ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

antiretroviral therapy; cure; nonhuman primate; simian immunodeficiency viruses

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN VIRUS; VIROLOGY; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; ANTI-RETROVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84880333413     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328361cf40     Document Type: Review

References (85)

1. Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1:1284-1290.
2. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188.
3. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4\+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517.
4. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-1295.
5. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.
6. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
7. Demberg T, Brocca-Cofano E, Xiao P, et al. Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J Virol 2012; 86:12591-12604.
8. Dunham RM, Gordon SN, Vaccari M, et al. Preclinical evaluation of HIV eradication strategies in the simian immunodeficiency virus-infected rhesus macaque: A pilot study testing inhibition of indoleamine 2, 3-dioxygenase. AIDS Res Hum Retrovirus 2012.
9. Lewis MG, Norelli S, Collins M, et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 2010; 7:21.
10. Lori F, Lewis MG, Xu J, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000; 290:1591-1593.
11. Lugli E, Mueller YM, Lewis MG, et al. IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques. Blood 2011; 118:2520-2529.
12. Horiike M, Iwami S, Kodama M, et al. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology 2012; 423:107-118.
13. Leone A, Rohankhedkar M, Okoye A, et al. Increased CD4\+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses. J Immunol 2010; 185:1650-1659.
14. zur Megede J, Sanders-Beer B, Silvera P, et al. Atherapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retroviruses 2008; 24:1103-1116.
15. Deere JD, Higgins J, Cannavo E, et al. Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. PLoS One 2010; 5:e11640.
16. Hofman MJ, Higgins J, Matthews TB, et al. Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Anti-microb Agents Chemother 2004; 48:3483-3490.
17. North TW, Van Rompay KK, Higgins J, et al. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a re-combinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol 2005; 79:7349-7354.
18. North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84:2913-2922.
19. Pandrea I, Gaufin T, Gautam R, et al. Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4\+ T cells and is reverted by CD8\+ cell depletion. PLoS Pathog 2011; 7:e1002170.
20. Jasny E, Geer S, Frank I, et al. Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 61:425-435.
21. Vagenas P, Aravantinou M, Williams VG, et al. A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One 2010; 5:e12891.
22. Shen A, Zink MC, Mankowski JL, et al. Resting CD4\+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 2003; 77:4938-4949.
23. Shen A, Yang HC, Zhou Y, et al. Novel pathway for induction of latent virus from resting CD4(\+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol 2007; 81:1660-1670.
24. Clements JE, Li M, Gama L, et al. The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretro-viral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol 2005; 11:180-189.
25. Clements JE, Gama L, Graham DR, et al. A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system. Curr Opin HIV AIDS 2011; 6:37-42.
26. Dinoso JB, Rabi SA, Blankson JN, et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83:9247-9257.
27. Graham DR, Gama L, Queen SE, et al. Initiation of HAART during acute simian immunodeficiency virus infection rapidly controls virus replication in the CNS by enhancing immune activity and preserving protective immune responses. J Neurovirol 2011; 17:120-130.
28. Queen SE, Mears BM, Kelly KM, et al. Replication-competent simian immunodeficiency virus (SIV) Gag escape mutations archived in latent reser voirs during antiretroviral treatment of SIV-infected macaques. J Virol 2011; 85:9167-9175.
29. Zink MC, Brice AK, Kelly KM, et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 2010; 202:161-170.
30. Ambrose Z, Palmer S, Boltz VF, et al. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol 2007; 81:12145-12155.
31. Boltz VF, Ambrose Z, Kearney MF, et al. Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus con taining human immunodeficiency virus reverse transcriptase. J Virol 2012;86:12525-12530.
32. Kearney M, Spindler J, Shao W, et al. Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J Virol 2011; 85:1067-1076.
33. Shao W, Kearney M, Maldarelli F, et al. RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy. Retrovirology 2009; 6:101.
34. Hatziioannou T, Ambrose Z, Chung NP, et al. A macaque model of HIV-1 infection. Proc Natl Acad Sci USA 2009; 106:4425-4429.
35. Thippeshappa R, Polacino P, Yu Kimata MT, et al. Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol 2011; 85:3767-3779.
36. Benlhassan-Chahour K, Penit C, Dioszeghy V, et al. Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J Virol 2003; 77:12479-12493.
37. Bourry O, Mannioui A, Sellier P, et al. Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology 2010; 7:78.
38. Moreau M, Le Tortorec A, Deleage C, et al. Impact of short-term HAART initiated during the chronic stage or shortly postexposure on SIV infection of male genital organs. PLoS One 2012; 7:e37348.
39. Kuroishi A, Saito A, Shingai Y, et al. Modification of a loop sequence between alpha-helices 6 and 7 of virus capsid (CA) protein in a human immunodeficiency virus type 1 (HIV-1) derivative that has simian immunodeficiency virus (SIVmac239) vif and CA alpha-helices 4 and 5 loop improves replication in cynomolgus monkey cells. Retrovirology 2009; 6:70.
40. Whetter LE, Ojukwu IC, Novembre FJ, Dewhurst S. Pathogenesis of simian immunodeficiency virus infection. J Gen Virol 1999; 80 (Pt 7):1557-1568.
41. Zink MC, Suryanarayana K, Mankowski JL, et al. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 1999; 73:10480-10488.
42. Uberla K, Stahl-Hennig C, Bottiger D, et al. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1995; 92:8210-8214.
43. Ambrose Z, Boltz V, Palmer S, et al. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol 2004; 78:13553-13561.
44. Balzarini J, De Clercq E, Uberla K. SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1-specific reverse transcriptase inhibitors after passage in rhesus macaques. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:1-4.
45. Balzarini J, Weeger M, Camarasa MJ, et al. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific nonnucleoside reverse transcriptase inhibitors. Biochem Biophys Res Com-mun 1995; 211:850-856.
46. O'Connor DH, Mothe BR, Weinfurter JT, et al. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J Virol 2003; 77:9029-9040.
47. Loffredo JT, FriedrichTC, Leon EJ, et al. CD8+T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation. PLoS One 2007; 2:e1152.
48. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-411.
49. Hendel H, Caillat-Zucman S, Lebuanec H, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol 1999; 162:6942-6946.
50. Deng K, Zink MC, Clements JE, Siliciano RF. A quantitative measurement of antiviral activity of antihuman immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: dose-response curve slope strongly influences class-specific inhibitory potential. J Virol 2012; 86:11368-11372.
51. Cohen J. Tissue says blood is misleading, confusing HIV cure efforts. Science 2011; 334:1614.
52. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52:3144-3160.
53. Radzio J, Aung W, Holder A, et al. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One 2012; 7:e50632.
54. Murry JP, Higgins J, Matthews TB, et al. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. J Virol 2003; 77:1120-1130.
55. Brandin E, Thorstensson R, Bonhoeffer S, Albert J. Rapid viral decay in simian immunodeficiency virus-infected macaques receiving quadruple antiretroviral therapy. J Virol 2006; 80:9861-9864.
56. Vaccari M, Boasso A, Fenizia C, et al. Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2', 3'-dideox-yinosine and stavudine following cytotoxic-T-lymphocyte-associated antigen 4 and indoleamine 2, 3-dioxygenase blockade. J Virol 2012; 86:108-113.
57. Zuber B, Bottiger D.Benthin R, ten Haaft P, Heeney J, Wahren B, Oberg B. An in vivo model for HIV resistance development. AIDS Res Hum Retroviruses 2001; 17:631-635.
58. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004; 305:528-532.
59. Shytaj IL, Norelli S, Chirullo B, et al. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 2012; 8:e1002774.
60. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infectioninmacaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270:1197-1199.
61. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-4273.
62. Van Rompay KK, Matthews TB, Higgins J, et al. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol 2002; 76:6083-6092.
63. Sanders-Beer BE, Spano YY, Golighty D, et al. Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose anti-retroviral therapy. AIDS Res Ther 2011; 8:3.
64. Lifson JD, Piatak M Jr, Cline AN, et al. Transient early postinoculation antire-troviral treatment facilitates controlled infection with sparing of CD4\+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol 2003; 32:201-210.
65. Hel Z, Venzon D, Poudyal M, et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 2000; 6:1140-1146.
66. Sellier P, Mannioui A, Bourry O, et al. Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. PLoS One 2010; 5:e10570.
67. Kader M, Hassan WM, Eberly M, et al. Antiretroviral therapy prior to acute viral replication preserves CD4 T cells in the periphery but not in rectal mucosa during acute simian immunodeficiency virus infection. J Virol 2008; 82:11467-11471.
68. Lifson JD, Rossio JL, Arnaout R, et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from re-challenge following transient postinoculation antiretroviral treatment. J Virol 2000; 74:2584-2593.
69. von Wyl V, Gianella S, Fischer M, et al. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One 2011; 6:e27463.
70. Steingrover R, Pogany K, Fernandez Garcia E, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008; 22:1583-1588.
71. Hamlyn E, Ewings FM, Porter K, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One 2012; 7:e43754.
72. Cline AN, Bess JW, Piatak M Jr, Lifson JD. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 2005; 34:303-312.
73. Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523-527.
74. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
75. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282:1627-1632.
76. Fischer M, Gunthard HF, Opravil M, et al. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Res Hum Retroviruses 2000; 16: 1135-1140.
77. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcrip-tase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536.
78. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-3884.
79. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
80. Brenchley JM, Vinton C, Tabb B, et al. Differential infection patterns of CD4\+ T cells and lymphoid tissue viral burden distinguish progressive and non-progressive lentiviral infections. Blood 2012; 120:4172-4181.
81. Wang F, Flanagan J, Su N, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2012; 14:22-29.
82. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37:377-388.
83. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantita-tion of latently infected, resting CD4\+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304:3-15.
84. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293-299.
85. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012; 63:95-111.